Swiss National Bank Has $26.93 Million Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Swiss National Bank lowered its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 4.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 145,900 shares of the medical research company's stock after selling 6,900 shares during the quarter. Swiss National Bank owned approximately 0.29% of Charles River Laboratories International worth $26,933,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Versant Capital Management Inc increased its position in shares of Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock worth $30,000 after acquiring an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. grew its position in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock worth $35,000 after purchasing an additional 65 shares in the last quarter. Assetmark Inc. grew its position in Charles River Laboratories International by 1,153.3% during the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company's stock worth $37,000 after purchasing an additional 173 shares in the last quarter. Tortoise Investment Management LLC boosted its position in shares of Charles River Laboratories International by 77.7% in the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock worth $49,000 after buying an additional 115 shares during the period. Finally, ORG Wealth Partners LLC purchased a new position in shares of Charles River Laboratories International during the fourth quarter valued at $56,000. Institutional investors and hedge funds own 98.91% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

CRL has been the subject of a number of research analyst reports. Redburn Atlantic raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price target for the company in a research report on Monday, March 3rd. Citigroup upgraded shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and increased their target price for the stock from $155.00 to $175.00 in a research report on Tuesday, March 4th. William Blair cut shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 22nd. Barclays reduced their price objective on Charles River Laboratories International from $205.00 to $166.00 and set an "equal weight" rating for the company in a research report on Tuesday, February 18th. Finally, Robert W. Baird dropped their target price on Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating on the stock in a research report on Thursday, February 20th. One analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $189.77.

Charles River Laboratories International Stock Performance

Shares of Charles River Laboratories International stock traded up $1.94 during trading on Friday, reaching $167.29. The company's stock had a trading volume of 1,629,017 shares, compared to its average volume of 723,009. Charles River Laboratories International, Inc. has a one year low of $150.79 and a one year high of $274.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The firm has a market cap of $8.55 billion, a price-to-earnings ratio of 1,115.26, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The business's fifty day moving average price is $166.49 and its 200-day moving average price is $183.98.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. During the same quarter last year, the firm posted $2.46 EPS. The company's revenue was down 1.1% on a year-over-year basis. As a group, equities research analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Insider Buying and Selling

In related news, COO Birgit Girshick bought 1,514 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 20th. The stock was acquired at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the purchase, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. This represents a 2.83 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Joseph W. Laplume sold 4,400 shares of the business's stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the transaction, the executive vice president now owns 20,013 shares in the company, valued at $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).